Tagged: teva Toggle Comment Threads | Keyboard Shortcuts

  • NoCamels 10:00 am on August 4, 2016 Permalink
    Tags: Allergan, , , teva,   

    Teva Completes $40B Purchase Of Allergan 

    tevaAugust 4, 2016 | Israeli pharmaceutical giant Teva Pharmaceutical completed its $40 billion acquisition of the generics arm of rival Allergan on Tuesday, a move Teva hailed as confirmation of its intention to become one of the world’s largest drugmakers. The $40 billion deal, the largest in Israeli history, was agreed last year but finally confirmed on Tuesday. Allergan Generics was the third largest in the same market by sales, and the acquisition gives Teva a large market lead and catapults it into the top 10 pharmaceutical firms globally, according to the company’s figures.

     
  • NoCamels 10:15 am on March 27, 2016 Permalink
    Tags: asthma treatments, CINQAIR, Israeli asthma solution, teva,   

    Teva’s Asthma Treatment Approved By FDA 

    tevaMarch 27, 2016 The US Food and Drug Administration (FDA) has approved Israel’s Teva Pharmaceutical Industries Ltd. CINQAIR injection for treating asthma. The drug treats asthma in adults who have a history of severe attacks despite taking medication. In the studies on which FDA approval was based, treatment with CINQAIR was associated with reduction in asthma exacerbations of up to 59 percent as well as significant improvement in lung function, symptoms, and asthma-related quality of life. This is the first approval of CINQAIR (reslizumab) anywhere in the world. The treatment is expected to become commercially available to patients, by prescription, during the second quarter of 2016. Teva was founded in 1901 and is currently headed by CEO Erez Vigodman.

     
     
  • NoCamels 4:11 pm on March 15, 2016 Permalink
    Tags: erectile dysfunction, generic drugs, teva, Viagra   

    Teva Gets FDA Approval For First-ever Generic Viagra 

    tevaMarch 15, 2016 The US Food and Drug Administration (FDA) has awarded Israel’s Teva Pharmaceutical Industries Ltd. approval for the first-ever generic version of Viagra. Teva’s generic version, which will be available to the public in the US from December 11 2017, will be available in 25, 50 and 100 milligram tablets and Teva will have 180 days exclusive generic marketing. Viagra is a branded drug produced and marketed by Pfizer. After protracted patent litigation, in which Pfizer claimed its patent was good until 2020, the two companies came to a compromise agreement in 2013, allowing Teva to market a generic version of the drug from December 2017.

     

     
  • Anouk Lorie 1:22 pm on November 26, 2015 Permalink
    Tags: CGRP antagonists, Heptares Therapeutics, , migrane, small-molecule calcitonin gene-related peptide antagonists, teva, teva migrane treatment, teva migrane uk investment, teva pharma uk investment   

    Teva Invests $10M In Heptares’ Migraine Treatment 

    tevaNovember 26, 2015 | Israeli pharmaceutical giant Teva and UK-based Heptares Therapeutics, a unit of Sosei Group Corporation, have announced a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine headaches. Heptares will receive an upfront payment of $10 million, and will be eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the partnership.

     
  • Anouk Lorie 11:21 am on October 19, 2015 Permalink
    Tags: Fresenius, kidney dialysis, kidney dialysis israel, Nephromor, renal dialysis israel, teva, teva dialysis   

    Report: Teva Sells Dialysis Division For $90M 

    tevaOctober 19, 2015 | German dialysis company Fresenius Medical Care has acquired the Nephromor chain of community dialysis centers, owned by Israeli pharmaceutical giant Teva and Israeli healthcare service provider Clalit, Globes reports. The sale price is estimated to be between $70 and $90 million. Founded in 1994, Nephromor provides dialysis services – a life-support treatment that supports the functioning of impaired kidneys.

     
  • Anouk Lorie 2:03 pm on October 12, 2015 Permalink
    Tags: , pharma m and a, pharma m&a, pharma news, tase listing, , teva   

    Myaln Files Request To List On Tel Aviv Stock Exchange 

    MylanOctober 12, 2015 | Dutch drug-maker Mylan formally filed a request to list on the Tel Aviv Stock Exchange (TASE) as part of the company’s ongoing hostile bid for the Irish pharmaceutical Perrigo, which also trades on the TASE. Israeli pharma companies made M&A headlines earlier this year when Teva pursued a hostile takeover of Mylan, and in order to fend off the bid, Mylan pursued its own hostile takeover of Perrigo. Teva has since abandoned its bid in favor of Allergan’s generic drug business. However, Mylan has stayed its course and become engrossed in a legal battle, in which both Mylan and Perrigo have filed suits regarding share purchases in US district courts.

     
  • einat 4:46 pm on March 30, 2015 Permalink
    Tags: , Israeli pharmaceutical company, teva, Teva acquisition of Auspex   

    Teva To Acquire Auspex For $3.5B 

    tevaMarch 30, 2015 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals for $3.5 billion. The acquisition will strengthen Teva’s portfolio of treatments for the central nervous system. Teva was originally founded in 1901 as Salomon, Levin, and Elstein.

     
  • Anouk Lorie 1:00 pm on November 5, 2014 Permalink
    Tags: , , Laquinimod, teva, teva huntington's disease treatment, teva neurodegenerative drugs, teva ppms treatment   

    Teva Begins Phase II Trials On Laquinimod Drug For MS, Huntington’s Disease 

    tevaNovember 5, 2014 | The Israeli pharmaceutical company Teva and Active Biotech will expand the Laquinimod clinical development program into Phase II trials. The trials will evaluate the ability of the Laquinimod drug to treat primary progressive multiple sclerosis (PPMS) as well as Huntington’s disease. This would be the first treatment for both PPMS and Huntington’s disease beyond symptom management. The study, called ARPEGGIO, will evaluate the efficacy, safety and tolerability of the Laquinimod drug in patients with PPMS, and the LEGATO-HD trial will test the efficacy and safety of the drug use on individuals with Huntington’s disease. Teva Pharmaceutical Industries was founded in 1901 by Eli Hurvitz.

     
  • Anouk Lorie 1:42 pm on September 3, 2014 Permalink
    Tags: advanced asthma solutions, ashtma treatments, , , phase III trial, teva, teva asthma treatments,   

    Teva Reports Successful Phase III Trials For Asthma Drug 

    Teva Makes $149M Offer For American Company NuPatheSeptember 3, 2014 | Teva Pharmaceutical Industries reported that its reslizumab asthma treatment saw positive Phase III trial results. According to the company, the drug was able to prevent serious asthma attacks in two of the case studies for the Phase III trial, showing a reduction in the number of attacks by 50 to 60 percent. “The consistent results from these duplicate Phase III trials demonstrating substantial reductions in asthma exacerbations are impressive,” said Professor Mario Castro, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine and lead investigator. Teva was founded in 1901 and is currently headed by CEO Erez Vigodman.

     
  • Anouk Lorie 1:33 pm on August 27, 2014 Permalink
    Tags: , indian-israeli partnerships, , pharmaceuticals israel, teva, teva anti-cancer drug, venus remedies   

    Teva And Venus Remedies Partner On Anti-Cancer Drug 

    Teva Makes $149M Offer For American Company NuPatheAugust 27, 2014 | Teva Pharmaceuticals and Indian company Venus Remedies entered into a collaborative agreement for the sale of an anti-cancer drug in the Canadian market. According to the agreement, Venus Remedies will manufacture the drug and will assist Teva in registering the drug in Canada. Venus will also use its manufacturing capabilities to support Teva enhance its business in the Canadian market. Teva is an international pharmaceutical company headquartered in Petah Tikvah, Israel, founded in 1901.

     
c
Compose new post
j
Next post/Next comment
k
Previous post/Previous comment
r
Reply
e
Edit
o
Show/Hide comments
t
Go to top
l
Go to login
h
Show/Hide help
shift + esc
Cancel